Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sheng

Showing results (201-210 of 208) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 208 results.
Allergologia Et Immunopathologia|June 21, 2017
The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East ChinaJ-L Liu, W-X Ning, S-X Li, et al.
Research Square|April 2, 2024
Addressing differences in cancer: a framework for synergistic programming in cancer prevention and controlCiaran M Fairman, Christine M Kava, K Beima-Sofie, et al.
Lupus|June 3, 2010
TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han populationC-F He, Y-S Liu, Y-L Cheng, et al.
Journal of Viral Hepatitis|October 29, 2017
Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective studyX Liang, Q Xie, D Tan, et al.
Chemmedchem|December 7, 2020
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*Kai S Yang, Xinyu R Ma, Yuying Ma, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease InhibitorsKai S Yang, Xinyu R Ma, Yuying Ma, et al.
The British Journal of Dermatology|February 2, 2017
Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and subphenotypes in the Han Chinese populationL L Wen, Z W Zhu, C Yang, et al.
Zhonghua Fu Chan Ke Za Zhi|January 29, 2026
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial]A M Zhao, Y Wang, W W Yang, et al.
Pageof 21

Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
Allergologia Et Immunopathologia|June 21, 2017
The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East ChinaJ-L Liu, W-X Ning, S-X Li, et al.
Research Square|April 2, 2024
Addressing differences in cancer: a framework for synergistic programming in cancer prevention and controlCiaran M Fairman, Christine M Kava, K Beima-Sofie, et al.
Lupus|June 3, 2010
TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han populationC-F He, Y-S Liu, Y-L Cheng, et al.
Journal of Viral Hepatitis|October 29, 2017
Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective studyX Liang, Q Xie, D Tan, et al.
Chemmedchem|December 7, 2020
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*Kai S Yang, Xinyu R Ma, Yuying Ma, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease InhibitorsKai S Yang, Xinyu R Ma, Yuying Ma, et al.
The British Journal of Dermatology|February 2, 2017
Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and subphenotypes in the Han Chinese populationL L Wen, Z W Zhu, C Yang, et al.
Zhonghua Fu Chan Ke Za Zhi|January 29, 2026
[Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial]A M Zhao, Y Wang, W W Yang, et al.
Pageof 21